Raul Santos Shares The Results of ORION-16: On The Efficacy and Safety of Inclisiran
Raul Santos, Researcher at ARO Hospital Israelita Albert Einstein, shared on LinkedIn:
”I’m delighted to share the results of ORION-16, which demonstrate the efficacy and safety of Inclisiran, a siRNA inhibitor of PCSK9, in pediatric patients with heterozygous familial hypercholesterolemia (FH) who had elevated LDL-C despite statin therapy.
Overall, LDL-C was reduced by 28-34%, with excellent tolerability.
Results are consistent with those of monoclonal antibodies, a 34-45% reduction that we had demonstrated in recent years.
Apparently, pediatric patients present less intense responses, albeit variable from person to person, than adults, despite similar reductions in circulating PCSK9.
In my opinion, this may result in possible lower adherence to baseline medications that were not disclosed or due to a different biology. Indeed, children and adolescents are not miniature adults.
ORION-16 reinforces the efficacy and safety of PCSK9 inhibitors in pediatric heterozygous FH.
It opens the possibility of a different posology to reduce LDL-C in patients who have severe hypercholesterolemia and remain with very high LDL-C despite statin and or ezetimibe therapy.
I’d like to thank Prof. Albert Wiegman and Novartis for the possibility to participate in this study.”
Read the full article here.
Article: Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial
Authors: Albert Wiegman, Amy L. Peterson, Eric Bruckert, Joep C. Defesche, Anja Schweizer, Jean Bergeron, María J. Chueca, Jeanine E. Roeters van Lennep, Raul D. Santos, Karl Otfried Schwab, Anastasia Lesogor, Sijia Zhang, Robert A. Hegele
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026